TD Waterhouse Canada Inc. Acquires 36,212 Shares of Guardant Health, Inc. $GH

TD Waterhouse Canada Inc. boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 624.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,009 shares of the company’s stock after acquiring an additional 36,212 shares during the period. TD Waterhouse Canada Inc.’s holdings in Guardant Health were worth $7,352,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. KOM Wealth Management Group LLC acquired a new stake in shares of Guardant Health during the third quarter worth about $203,000. NFSG Corp acquired a new position in shares of Guardant Health in the 3rd quarter valued at approximately $33,000. V Square Quantitative Management LLC grew its position in shares of Guardant Health by 55.3% in the 3rd quarter. V Square Quantitative Management LLC now owns 407 shares of the company’s stock valued at $73,000 after purchasing an additional 145 shares during the period. Triasima Portfolio Management inc. acquired a new position in shares of Guardant Health in the 3rd quarter valued at approximately $6,089,000. Finally, First Pacific Financial increased its stake in Guardant Health by 14.7% during the 3rd quarter. First Pacific Financial now owns 1,522 shares of the company’s stock worth $271,000 after purchasing an additional 195 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of research reports. Royal Bank Of Canada lifted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. The Goldman Sachs Group reissued a “buy” rating and set a $210.00 price objective on shares of Guardant Health in a research report on Friday, July 31st. Sanford C. Bernstein restated an “outperform” rating and set a $210.00 price objective on shares of Guardant Health in a report on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday. Finally, Stephens boosted their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.00.

Insider Buying and Selling

In other news, CEO Amirali Talasaz sold 37,500 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the transaction, the chief executive officer directly owned 37,500 shares in the company, valued at $6,343,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ian Clark sold 14,180 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the completion of the sale, the director owned 2,975 shares in the company, valued at $472,787. This represents a 82.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 178,940 shares of company stock worth $30,070,911. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $157.88 on Tuesday. The stock has a 50 day moving average price of $167.75 and a 200 day moving average price of $139.99. Guardant Health, Inc. has a 52 week low of $65.96 and a 52 week high of $191.05. The stock has a market capitalization of $21.19 billion, a PE ratio of -45.24 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.44) earnings per share. As a group, research analysts forecast that Guardant Health, Inc. will post -3.02 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.